Previous close | 28.17 |
Open | 28.34 |
Bid | 28.35 x 0 |
Ask | 29.04 x 0 |
Day's range | 28.29 - 28.35 |
52-week range | 15.20 - 31.28 |
Volume | 50 |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
AstraZeneca's (AZN) Enhertu gets EU approval for metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens.
AstraZeneca's (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.
Here's why AstraZeneca agreed to pay Daiichi Sankyo another enormous sum to develop and commercialize an experimental cancer drug.